Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD
Pulmonary Pharmacology and Therapeutics, Volume 21, No. 5, Year 2008
Notification
URL copied to clipboard!
Description
Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the use of forced expiratory volume in 1 s (FEV1) to assess airways reversibility. The American Thoracic Society (ATS) and the European Respiratory Society (ERS) recommend FEV1 and/or forced vital capacity (FVC). This study assessed whether FVC detects reversibility in more chronic obstructive pulmonary disease (COPD) patients than FEV1 after acute short-acting bronchodilator inhalation. Methods: Plethysmographic data of 168 consecutive stable male COPD patients who underwent reversibility testing were analyzed. Results: Seventy-seven patients showed a clinically significant increase in FVC, whereas only 49 patients showed a clinically significant increase in FEV1. Thus, FVC detected reversibility in 57% more patients than FEV1. Of the 90 patients showing clinically significant reversibility, FEV1 did not detect 41 patients that FVC detected, indicating a 45% difference. Conclusion: FEV1 underestimates acute bronchodilation effects. FVC should thus be a primary clinical outcome measure of bronchodilator reversibility in COPD, as it detects reversibility in more patients. This message, forgotten by GOLD, should be promoted in future consensus statements. Crown Copyright © 2008.
Authors & Co-Authors
Ben saad, Helmi
Tunisia, Sousse
Service de Physiologie et Des Explorations Fonctionnelles
France, Montpellier
Centre Hospitalier Universitaire de Montpellier
France, Paris
Inserm
France, Montpellier
Université de Montpellier
Préfaut, Christian G.
France, Montpellier
Centre Hospitalier Universitaire de Montpellier
France, Paris
Inserm
France, Montpellier
Université de Montpellier
Tabka, Zouhaïr
Tunisia, Sousse
Service de Physiologie et Des Explorations Fonctionnelles
Zbidi, Abdelkarim
Tunisia, Sousse
Service de Physiologie et Des Explorations Fonctionnelles
Hayot, Maurice
France, Montpellier
Centre Hospitalier Universitaire de Montpellier
France, Paris
Inserm
France, Montpellier
Université de Montpellier
Statistics
Citations: 48
Authors: 5
Affiliations: 4
Identifiers
Doi:
10.1016/j.pupt.2008.04.005
ISSN:
10945539
e-ISSN:
15229629
Research Areas
Noncommunicable Diseases
Participants Gender
Male